Skip to main navigationSkip to main content
The University of Southampton
We're launching a new website soon and would love your feedback. See the new design

Dr Igor Vorechovsky MD, PhD

Principal Research Fellow

Dr Igor Vorechovsky's photo
Related links

Dr Igor Vorechovsky is Principal Research Fellow within Medicine at the University of Southampton. Dr Vorechovsky joined the Faculty of Medicine in 2002 as a Lecturer.

Why do we have genes in pieces? This arrangement greatly contributes to human morbidity.

Having graduated in medicine from the Purkynje University Brno, he was trained in general Paediatrics and specialised in Clinical Genetics. He completed his PhD 1989 in molecular genetics. He held clinical or research positions in the Institute of Child Health, Paterson Institute, Karolinska Institute and academic positions in UCL and Southampton University.

Dr Vorechovsky leads a group that investigates molecular mechanisms of predisposition to genetic disease at the level of RNA processing and their repair using non-genetic means. His past achievements include, for example, isolation of the gene for the first described immunodeficiency X-linked agammaglobulinaemia (Nature 361:226-233, Science 261:355-368) and identification of genes and critical mutations underlying several cancer-predisposing genetic disorders (Cell 85: 841-851, Nature Genetics 17:96-99). He is a co-author of >100 peer-reviewed articles, cited altogether >7,000x (h-index 38). Potential students, post-doctoral scientists or clinician scientists who are interested in joining his group are encouraged to contact Dr Vorechovsky.


1983 Doctor of Medicine Purkynje University
1989 Ph.D. in Genetics Charles University

Appointments held

1983-89 Institute of Child Health; Research Fellow

1989-91 Paterson Institute; Visiting Fellow

1991-95 Karolinska Institute; Research Scientist

1995-02 University College London, Lecturer

Research interests

Eukaryotic genes contain intervening sequences or introns that must be removed from precursor messenger RNA (pre-mRNA) to ensure correct gene expression. This process is known as pre-mRNA splicing and is mediated by conserved sequences at the 5’ and 3’ splice sites. These signals do not contain sufficient information to accurately identify gene coding sequences and many additional sequence features exist in the pre-mRNA that navigate the splicing machinery to the appropriate location. These features include exonic and intronic enhancer and silencer elements, which activate and repress inclusion of coding sequences in mRNA and are involved in numerous structural interactions and ligand binding.

Our group is interested in identifying molecular mechanisms responsible for genetic susceptibility to complex genetic diseases at the level of pre-mRNA splicing. DNA variants in the human genome often influence efficiency of intron removal and downstream gene expression pathways, such as transcription and translation. Understanding how disease-predisposing variants interact with gene expression machinery is likely to be a prerequisite for future preventive and therapeutic approaches, such as antisense strategies that efficiently repair incorrectly spliced gene segments in vitro (Nucleic Acids Res. 2011 May 23) and in vivo (Genes Dev. 24:1634-1644, 2010).

Examples of project areas:

Molecular mechanisms of genetic susceptibility to type 1 diabetes at IDDM2

IDDM2 is a locus on chromosome 11 that contains genetic variants predisposing to and protecting from type 1 diabetes, an autoimmune disorder characterized by self-destruction of pancreatic ß cells. This locus contains a gene encoding human proinsulin (INS). For example, we identified INS variants that influence pre-mRNA splicing and downstream RNA remodeling and are investigating which RNA-protein interactions are affected (Diabetes 55:260-264; 2006; Human Genetics 128:383-400; 2010). In addition, we identified auxiliary splicing elements that are responsible for haplotype-specific splicing of HLA-DQB1, a gene in the major histocompatiblity complex that predisposes to a large number of autoimmune disorders (Human Molecular Genetics 13:3189-3202; 2004 and Journal of Immunology 176:2381-2388; 2006).

Development of bioinformatic tools that facilitate prediction of aberrant splice sites in human disease genes

The database of cryptic and de novo 3’ and 5’ splice sites (Nucleic Acids Research 39: D86-D91, 2011) ( serves molecular and clinical geneticists, the RNA community and specialists in the field of bioinformatics to identify splicing mutations and auxiliary splicing signals. Initial analysis of the database has provided new insights into the mutation pattern underlying aberrant splice sites and their computational prediction (Nucleic Acids Research 33:4882-98; 2005, Nucleic Acids Research 34:4630-41; 2006 and Nucleic Acids Research 35:4250-4263; 2007) and into auxiliary splicing sequences that activate or repress their utilization (Nucleic Acids Research 35:6399-413; 2007). It also serves to develop and optimize predictive tools that distinguish exon skipping and cryptic splice-site activation (Eur J Hum Genet. 7:759-65.2009), identify exon-skipping substitutions in exons (Hum Mutat. 32:436-44, 2011) and is also helpful for addressing unresolved hypotheses, such as intron origin (Nucleic Acids Res. 2011 Apr 5.).

Disease-associated exonization of repetitive sequences

Approximately half of the human genome consists of repetitive sequences that were previously regarded as ‘junk DNA’ without any function. These elements are now recognized to be an important source of both regulatory and coding sequences. They are frequent in introns, may influence their removal and contribute to fine-tuning of gene expression. Mutations in repetitive elements may lead to constitutive splicing and cause hereditary disease (Hum Genet. 127:135-54, 2010) (Hum Mutat. 30:823-31, 2009) (Pediatr Res. 67:444, 2010). A common outcome of intronic mutations is partial exonization of intronic repeats and their low-level inclusion to mRNA. Alternative splicing of these intronic segments may lead to their exaptation, a gain of new coding or regulatory function. We are investigating molecular pathways involved in recognition of common human repetitive sequences by the spliceosome, the largest RNA-protein complex in the cell (Mol Cell Biol 25:6912-20; 2005 and Nucleic Acids Research 33:3897-906; 2005).

Auxiliary factor of U2 small nuclear ribonucleoprotein (U2AF) in haematological malignancies

U2AF is a stable heterodimer that binds to most 3’ splice sites to facilitate branch point recognition and accurate intron removal. It consists of a 65- and 35-kDa subunits that both bind the pre-mRNA early during spliceosome assembly. Recent studies have shown recurrent somatic mutations in genes encoding U2AF and their interaction partners in cancer, suggesting the existence of a shared oncogenic pathway initiated by impaired recognition of 3’ splice sites. We are studying global transcriptomic changes conferred by mutated U2AF subunits and regulation of their alternative splicing (Nucleic Acids Res 43:3747-3763, 2015).


Human Development and Health

Affiliate Department(s)

Human Development and Physiology

Postgraduate student supervision

2001 Liping Luo MsC PhD
2002 Aleksi Lahdesmaki PhD
2004 Lei Haixin PhD
2005 Jana Kralovicova PhD
2008 Ellen Copson PhD


Ana Lages

Faculty of Medicine

Steering Committee of PDA
Assessor of BM primary and intermediate exams, the 4th year in-depth studies, 3rd year assignments

National and International Responsibilities

Associate Editor of BMC journals
Peer reviewer of over 20 journals and research grant applications to 5 funding bodies
Member of the Human Genome Organization.
Registered Practitioner of the Higher Education Academy

Sort via:TypeorYear


IPLU facilitator and assessor

Dr Igor Vorechovsky
Phone: (023) 8120 6425 Fax: (023) 8120 4264 Email:

Room Number: SGH/DB/MP808

Share this profile Share this on Facebook Share this on Twitter Share this on Weibo
Privacy Settings